Trial reportBreast cancer research and treatment2009
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.
Trial report in Breast cancer research and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Circulating tumor cells in breast cancer and its association with tumor clinicopathological characteristics: a meta-analysis.Medical oncology (Northwood, London, England) · 2014Pooled it
- Trial
- Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.BioMed research international · 2014Trial
- Characterizing epithelial-mesenchymal transition-linked heterogeneity in breast cancer circulating tumor cells at a single-cell level.Molecular oncology · 2025Article
- Cancer metastasis: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2025Review
- Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach.Frontiers in medicine · 2025Article
- Article
- Article
- Impact of changing treatment strategy based on circulating tumor cells on postoperative survival of breast cancer.Frontiers in oncology · 2022Article
- Evolutionary model of brain tumor circulating cells: Cellular galaxy.World journal of clinical oncology · 2021Article
- Association between folate metabolism polymorphisms and breast cancer: a case-control study.Genetics and molecular biology · 2021Article
- Role of Plasma D-Dimer Levels in Breast Cancer Patients and Its Correlation with Clinical and Histopathological Stage.Indian journal of surgical oncology · 2018Article
- Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.Oncotarget · 2017Article
- Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.Journal of Cancer · 2016Article
- Monitoring cancer stem cells: insights into clinical oncology.OncoTargets and therapy · 2016Article
- Circulating tumor cells in newly diagnosed inflammatory breast cancer.Breast cancer research : BCR · 2015Article
- Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity.Frontiers in oncology · 2015Review
- HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.World journal of surgical oncology · 2014Article
- Clinical application of circulating tumor cells in breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2014Review
- Circulating tumor cells in breast cancer.Journal of carcinogenesis · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
introductionCirculating tumor cells (CTCs) correlate with worse prognosis in patients with metastatic breast cancer, but there are little data on CTCs in operable patients. We hypothesized that primary tumor characteristics would predict the likelihood of identifying CTCs in patients with operable breast cancer.
methodsClinical and pathological data from 92 patients with operable breast cancer were collected. The CellSearch system was used to detect CTCs in 30 ml of peripheral blood. CTCs were defined as nucleated cells lacking CD45 but expressing cytokeratins 8, 18, or 19. Univariate analysis was performed to determine if the presence of any primary tumor characteristic was predictive of CTCs. As a secondary objective we evaluated if nodal or bone marrow status was predictive of CTCs.
resultsThirty-eight percent of patients (35/92) had evidence of CTCs, with a median number of 1.0 CTC per CTC positive patient (range 1-22). HER2 status was the sole primary tumor characteristic that reliably predicted the presence of CTCs (P = 0.01, risk ratio = 3.66). No significant association was found between the presence of CTCs and tumor size (T), estrogen receptor (ER) status, progesterone receptor (PR) status, grade, histologic type, degree of nodal involvement (N), lymphovascular invasion (LVI) or Ki-67 proliferation. Bone marrow micrometastases were found in 17/64 (26.6%) of the patients but did not correlate with the presence of CTCs.
conclusionHER2 status was the only primary tumor characteristic that correlated with the presence of CTCs. Long-term follow-up will be required to determine the significance of CTCs in operable breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.